Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab (GSK3196165) vs Tofacitinib and Placebo in RA (contRAst 2)
NCT03970837Phase 3Terminated
- Sponsor
- GSK
- Start
- Jun 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of otilimab in rheumatoid arthritis (RA), sponsored by GSK. Started Jun 2019; status: terminated.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03970837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970837.